A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment in Patients with Multiple Sclerosis (MS)
Relative change from baseline in CSF NfL at 12 months
Endpoint detail
Serum NfL at 12 and 24 months, CSF and serum GFAP at 12 and 24 months, CSF biomarkers of chemokines (CXCL10, CXCL13), innate immuny (LCN2, CHIT1), complement system (C1QA, C5), and synapses (SNAP25, SV2A) at 12 months
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.